AbbVie Unveils New Oncology Data at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 32 minutes ago
0mins
Source: Newsfilter
- Oncology Pipeline Progress: AbbVie presented new data at the 2026 ASCO Annual Meeting, covering solid tumors and blood cancers, showcasing the company's ongoing investment and innovation in the oncology field.
- Prostate Cancer Findings: In a Phase 1 study for metastatic castration-resistant prostate cancer, ABBV-969 demonstrated a 45% objective response rate, with 67% of patients achieving over 50% reduction in PSA levels, indicating the drug's potential in heavily pretreated patients.
- Small Cell Lung Cancer Results: ABBV-706 achieved an 82% objective response rate in small cell lung cancer monotherapy, demonstrating promising efficacy in a patient population with poor prognosis, supporting further evaluation in this area.
- Multiple Myeloma New Therapy: Etentamig achieved a 64% objective response rate in heavily pretreated multiple myeloma patients, with 67% of patients showing minimal residual disease negativity after BCMA-directed therapy, indicating its effectiveness and safety in treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 212.300
Low
223.00
Averages
252.00
High
289.00
Current: 212.300
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Unveils New Data at ASCO Meeting Highlighting Oncology Pipeline
- Oncology Platform Progress: At the 2026 ASCO Annual Meeting, AbbVie showcased new data from its Top1i ADC and T-cell engager platforms, covering prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer, and multiple myeloma, demonstrating significant potential in solid tumors and blood cancers, thereby reinforcing the company's leadership in oncology treatment.
- Clinical Trial Results: AbbVie will present multiple clinical trial outcomes at the meeting, including studies on etentamig for relapsed/refractory multiple myeloma, highlighting its commitment to addressing unmet patient needs and potentially driving innovation in future treatment options.
- Investment and Strategy: AbbVie continues to invest in its antibody-drug conjugate (ADC) platform, emphasizing a diversified therapeutic portfolio designed to tackle the complexity and heterogeneity of cancer biology, thus enhancing market competitiveness and meeting diverse patient needs.
- Future Outlook: By showcasing its research findings at ASCO, AbbVie not only demonstrates its innovative capabilities in oncology but also lays the groundwork for future drug development and market promotion, potentially attracting more investor interest in its long-term growth prospects.
See More
AbbVie Unveils New Oncology Data at ASCO Meeting
- Oncology Pipeline Progress: AbbVie presented new data at the 2026 ASCO Annual Meeting, covering solid tumors and blood cancers, showcasing the company's ongoing investment and innovation in the oncology field.
- Prostate Cancer Findings: In a Phase 1 study for metastatic castration-resistant prostate cancer, ABBV-969 demonstrated a 45% objective response rate, with 67% of patients achieving over 50% reduction in PSA levels, indicating the drug's potential in heavily pretreated patients.
- Small Cell Lung Cancer Results: ABBV-706 achieved an 82% objective response rate in small cell lung cancer monotherapy, demonstrating promising efficacy in a patient population with poor prognosis, supporting further evaluation in this area.
- Multiple Myeloma New Therapy: Etentamig achieved a 64% objective response rate in heavily pretreated multiple myeloma patients, with 67% of patients showing minimal residual disease negativity after BCMA-directed therapy, indicating its effectiveness and safety in treatment.
See More
Seeking Stable Dividend Growth Amid Market Turbulence
- Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
- Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
- Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
- Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
See More
UCB's Bimzelx Outperforms AbbVie's Skyrizi in PsA Trial
- Clinical Trial Results: UCB's biologic Bimzelx demonstrated superiority over AbbVie's Skyrizi in the BE BOLD trial for PsA, achieving a 49.1% ACR50 at Week 16, significantly higher than Skyrizi's 38.4%, indicating stronger efficacy in symptom improvement.
- Secondary Endpoint Performance: Although Bimzelx showed a 43.0% improvement in Minimal Disease Activity (MDA) compared to Skyrizi's 39.9%, the difference lacked statistical significance, which limits the strength of its claims.
- Safety Comparison: The overall safety profiles of both treatments were comparable; however, Bimzelx had a higher treatment-emergent adverse event (TEAE) rate of 57% versus Skyrizi's 52%, suggesting a need for caution regarding potential adverse reactions with Bimzelx.
- Trial Scale and Significance: The BE BOLD trial enrolled over 500 adults with active PsA and is the first head-to-head trial to show statistically significant superiority for a biologic in ACR50 joint outcomes, marking a significant advancement for UCB in the PsA treatment landscape.
See More
Misleading Aspects of Stock Valuation
- AbbVie's High Valuation: AbbVie has a P/E ratio exceeding 100, and despite a mere 14% stock price increase over the past year, significantly lagging behind the S&P 500's 24%, this is primarily due to a drastic drop in net income to $188 million from nearly $1.6 billion last year, reflecting the impact of acquisition-related R&D expenses that have raised investor concerns about its high valuation.
- Forward P/E Advantage: Although AbbVie appears overvalued with a high P/E ratio, its forward P/E of 15, which accounts for analyst expectations of future performance, suggests that its actual value may be underestimated, making it an attractive option for long-term investors.
- CVS Health's Earnings Volatility: CVS Health's trailing P/E stands at 42, but the company reported a net loss of nearly $4 billion in Q3 2025, primarily due to a $5.7 billion goodwill impairment, which inflates its P/E ratio; however, its forward P/E drops to just 13, indicating significant investment potential.
- Positive Signal from Decreasing Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, indicating effective cost control, which may lead analysts to upgrade their outlook for the company, further lowering its forward P/E ratio.
See More
AbbVie and CVS Health Stock Analysis Reveals Misleading Valuations
- Misleading Earnings Multiples: AbbVie and CVS Health both exhibit trailing P/E ratios exceeding 40, appearing expensive at first glance; however, non-recurring expenses have distorted their earnings, potentially causing investors to overlook their true value.
- AbbVie's Financial Condition: AbbVie reported net income of $188 million for Q3 2025, a significant drop from nearly $1.6 billion in the prior year, primarily due to a $2.7 billion charge for R&D costs, which inflated its P/E ratio to over 100.
- CVS Health's Losses: CVS Health reported a net loss of nearly $4 billion in Q3 2025, largely due to a $5.7 billion goodwill impairment, resulting in a high trailing P/E of 42, while its forward P/E drops to 13, indicating its actual value may be underestimated.
- Declining Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, suggesting better financial health and potentially attracting more investor interest as the company enhances its bottom line.
See More
AbbVie Unveils New Data at ASCO Meeting Highlighting Oncology Pipeline
- Oncology Platform Progress: At the 2026 ASCO Annual Meeting, AbbVie showcased new data from its Top1i ADC and T-cell engager platforms, covering prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer, and multiple myeloma, demonstrating significant potential in solid tumors and blood cancers, thereby reinforcing the company's leadership in oncology treatment.
- Clinical Trial Results: AbbVie will present multiple clinical trial outcomes at the meeting, including studies on etentamig for relapsed/refractory multiple myeloma, highlighting its commitment to addressing unmet patient needs and potentially driving innovation in future treatment options.
- Investment and Strategy: AbbVie continues to invest in its antibody-drug conjugate (ADC) platform, emphasizing a diversified therapeutic portfolio designed to tackle the complexity and heterogeneity of cancer biology, thus enhancing market competitiveness and meeting diverse patient needs.
- Future Outlook: By showcasing its research findings at ASCO, AbbVie not only demonstrates its innovative capabilities in oncology but also lays the groundwork for future drug development and market promotion, potentially attracting more investor interest in its long-term growth prospects.
See More
AbbVie Unveils New Oncology Data at ASCO Meeting
- Oncology Pipeline Progress: AbbVie presented new data at the 2026 ASCO Annual Meeting, covering solid tumors and blood cancers, showcasing the company's ongoing investment and innovation in the oncology field.
- Prostate Cancer Findings: In a Phase 1 study for metastatic castration-resistant prostate cancer, ABBV-969 demonstrated a 45% objective response rate, with 67% of patients achieving over 50% reduction in PSA levels, indicating the drug's potential in heavily pretreated patients.
- Small Cell Lung Cancer Results: ABBV-706 achieved an 82% objective response rate in small cell lung cancer monotherapy, demonstrating promising efficacy in a patient population with poor prognosis, supporting further evaluation in this area.
- Multiple Myeloma New Therapy: Etentamig achieved a 64% objective response rate in heavily pretreated multiple myeloma patients, with 67% of patients showing minimal residual disease negativity after BCMA-directed therapy, indicating its effectiveness and safety in treatment.
See More
Seeking Stable Dividend Growth Amid Market Turbulence
- Dividend Growth Strategy: Trivariate Research emphasizes that in turbulent markets, investors should focus on companies with consistent dividend growth over the past five years for downside protection, especially as traditional defensive stocks now represent just over 10% of the S&P 500's market cap.
- Rollins Performance: Pest control company Rollins recently raised its dividend by over 10% to 18 cents per share, and despite a roughly 10% decline in its stock in 2026, analysts remain optimistic about its ability to deliver compounding growth, with Goldman Sachs reiterating a buy rating.
- Cheniere Energy Growth: Liquefied natural gas company Cheniere Energy increased its quarterly dividend by over 10% last October, currently yielding 0.9%, and its stock has risen 26% this year, benefiting from reduced LNG production in the Middle East.
- Analyst Support: Cheniere Energy's first-quarter results exceeded expectations, raising its adjusted EBITDA guidance to between $7.25 billion and $7.75 billion, with analysts bullish on its strong volume outlook and project execution, as 23 out of 24 analysts rate it a buy.
See More
UCB's Bimzelx Outperforms AbbVie's Skyrizi in PsA Trial
- Clinical Trial Results: UCB's biologic Bimzelx demonstrated superiority over AbbVie's Skyrizi in the BE BOLD trial for PsA, achieving a 49.1% ACR50 at Week 16, significantly higher than Skyrizi's 38.4%, indicating stronger efficacy in symptom improvement.
- Secondary Endpoint Performance: Although Bimzelx showed a 43.0% improvement in Minimal Disease Activity (MDA) compared to Skyrizi's 39.9%, the difference lacked statistical significance, which limits the strength of its claims.
- Safety Comparison: The overall safety profiles of both treatments were comparable; however, Bimzelx had a higher treatment-emergent adverse event (TEAE) rate of 57% versus Skyrizi's 52%, suggesting a need for caution regarding potential adverse reactions with Bimzelx.
- Trial Scale and Significance: The BE BOLD trial enrolled over 500 adults with active PsA and is the first head-to-head trial to show statistically significant superiority for a biologic in ACR50 joint outcomes, marking a significant advancement for UCB in the PsA treatment landscape.
See More
Misleading Aspects of Stock Valuation
- AbbVie's High Valuation: AbbVie has a P/E ratio exceeding 100, and despite a mere 14% stock price increase over the past year, significantly lagging behind the S&P 500's 24%, this is primarily due to a drastic drop in net income to $188 million from nearly $1.6 billion last year, reflecting the impact of acquisition-related R&D expenses that have raised investor concerns about its high valuation.
- Forward P/E Advantage: Although AbbVie appears overvalued with a high P/E ratio, its forward P/E of 15, which accounts for analyst expectations of future performance, suggests that its actual value may be underestimated, making it an attractive option for long-term investors.
- CVS Health's Earnings Volatility: CVS Health's trailing P/E stands at 42, but the company reported a net loss of nearly $4 billion in Q3 2025, primarily due to a $5.7 billion goodwill impairment, which inflates its P/E ratio; however, its forward P/E drops to just 13, indicating significant investment potential.
- Positive Signal from Decreasing Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, indicating effective cost control, which may lead analysts to upgrade their outlook for the company, further lowering its forward P/E ratio.
See More
AbbVie and CVS Health Stock Analysis Reveals Misleading Valuations
- Misleading Earnings Multiples: AbbVie and CVS Health both exhibit trailing P/E ratios exceeding 40, appearing expensive at first glance; however, non-recurring expenses have distorted their earnings, potentially causing investors to overlook their true value.
- AbbVie's Financial Condition: AbbVie reported net income of $188 million for Q3 2025, a significant drop from nearly $1.6 billion in the prior year, primarily due to a $2.7 billion charge for R&D costs, which inflated its P/E ratio to over 100.
- CVS Health's Losses: CVS Health reported a net loss of nearly $4 billion in Q3 2025, largely due to a $5.7 billion goodwill impairment, resulting in a high trailing P/E of 42, while its forward P/E drops to 13, indicating its actual value may be underestimated.
- Declining Medical Costs: CVS Health's medical benefits ratio improved to 84.6% in Q1 2026 from 87.3% a year earlier, suggesting better financial health and potentially attracting more investor interest as the company enhances its bottom line.
See More
